AbbVie nelle notizie
Creazione di farmaci biofarmaceutici
Tamtam ha trovato 20 articoli recenti su AbbVie.
- Stocks Pare Losses As Yields Slash Gains; AbbVie, Apple, Micron In Focus
- FDA Grants Breakthrough Therapy Designations to AbbVie's Temab-A in Colorectal and Lung Cancers
- AbbVie’s Temab-A receives two FDA Breakthrough statuses
- AbbVie Targets Jawline and Neck Aesthetics With New Botox and Juvéderm Study
- AbbVie Shares Rise After Hours on FDA Designations - AbbVie (NYSE:ABBV)
- Genmab and AbbVie’s Epkinly win, a rush of deals, Sarepta’s turnaround hopes, more
- AbbVie (ABBV) Pays Out More Than It Earns. How Long Can That Hold?
- AbbVie options flow shows 4:1 call-to-put ratio as stock rises
- AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
- Update: AbbVie Shares Rise After FDA Gives 2 Breakthrough Designations for Cancer Drug
- AbbVie price target raised to $320 from $280 at Scotiabank
- Should You Buy AbbVie Stock Before Oct. 30?
- AbbVie, Genmab report positive results from Phase III EPCORE DLBCL-2 trial
- Dual-acting drug from AbbVie, Genmab scores in frontline lymphoma trial
- HSBC Thinks AbbVie Can Climb to $315. Here's the Bull Case in Plain English.
- Better Dividend for Retirees: AbbVie vs. Merck
- Genmab and AbbVie Report Landmark Phase 3 Win for Epcoritamab Combo in Frontline DLBCL
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere
- AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
- Is AbbVie (ABBV) Still Undervalued On FDA Approval And Fresh Pipeline Data?
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come AbbVie?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili